<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02938806</url>
  </required_header>
  <id_info>
    <org_study_id>#160113</org_study_id>
    <nct_id>NCT02938806</nct_id>
  </id_info>
  <brief_title>The Effects of Type 1 Diabetes Mellitus and Increased Weight on Gut Microbiome and Urine Metabolome Profiles in Children</brief_title>
  <official_title>The Effects of Type 1 Diabetes Mellitus and Increased Weight on Gut Microbiome and Urine Metabolome Profiles in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study employs a cross-sectional design to profile the gut microbiome and urine&#xD;
      metabolome in overweight/obese children with type 1 diabetes (T1D).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will obtain stool and urine samples from subjects aged 7-17 years in 4&#xD;
      groups:&#xD;
&#xD;
        -  Group 1: Obese or overweight children within 3 years of diagnosis of T1D&#xD;
&#xD;
        -  Group 2: Normal weight children within 3 years of diagnosis of T1D&#xD;
&#xD;
        -  Group 3: Obese or overweight children without T1D&#xD;
&#xD;
        -  Group 4: Normal weight children without T1D&#xD;
&#xD;
      Type 1 diabetes will be defined according to American Diabetes Association criteria along&#xD;
      with the presence of pancreatic autoantibodies (GAD65, ICA512, or insulin autoantibodies).&#xD;
      Obese and overweight status will be defined by BMI &gt;85th percentile for age and gender&#xD;
      according to CDC criteria.&#xD;
&#xD;
      All subjects will provide one-time stool and first morning urine sample. Overweight or obese&#xD;
      subjects will additionally have a point of care blood glucose and hemoglobin A1c measurement&#xD;
      to ensure that they do not have diabetes.&#xD;
&#xD;
      The investigators will perform 16S rRNA sequencing of stool bacteria and mass spectrometry&#xD;
      measurement of urine metabolites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of gut microbial composition and diversity by 16S rRNA sequencing</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of urine metabolite concentrations measured by mass spectrometry</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Obese/overweight children with T1D</arm_group_label>
    <description>No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal weight children with T1D</arm_group_label>
    <description>No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese/overweight children, no diabetes</arm_group_label>
    <description>No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy, normal weight children</arm_group_label>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Healthy, normal weight children</arm_group_label>
    <arm_group_label>Normal weight children with T1D</arm_group_label>
    <arm_group_label>Obese/overweight children with T1D</arm_group_label>
    <arm_group_label>Obese/overweight children, no diabetes</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool Urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children aged 7-17 years with/without T1DM and with/without obese/overweight status in San&#xD;
        Diego, California&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 7 to 17 years&#xD;
&#xD;
          -  Diagnosis of diabetes will be defined by current American Diabetes Association&#xD;
             criteria ° (fasting glucose &gt; 126 mg/dl, 2 hour OGTT glucose &gt; 200 mg/dl; random&#xD;
             glucose &gt; 200 with symptoms of hyperglycemia; or HbA1c &gt; 6.5%)&#xD;
&#xD;
          -  Diabetes duration &lt; 3 years&#xD;
&#xD;
          -  Presence of pancreatic autoimmunity (GAD65, ICA512, or insulin autoantibody&#xD;
             positivity)&#xD;
&#xD;
          -  Adult caregiver willing to actively support study participation&#xD;
&#xD;
          -  Signed parental informed consent form and minor child informed assent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other significant organ system illness or condition (including psychiatric or&#xD;
             developmental disorder) that, in the opinion of the investigator, would prevent&#xD;
             participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rady Children's Hospital Endocrinology Department</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Boerner BP, Sarvetnick NE. Type 1 diabetes: role of intestinal microbiome in humans and mice. Ann N Y Acad Sci. 2011 Dec;1243:103-18. doi: 10.1111/j.1749-6632.2011.06340.x. Review.</citation>
    <PMID>22211896</PMID>
  </reference>
  <reference>
    <citation>Dunne JL, Triplett EW, Gevers D, Xavier R, Insel R, Danska J, Atkinson MA. The intestinal microbiome in type 1 diabetes. Clin Exp Immunol. 2014 Jul;177(1):30-7. doi: 10.1111/cei.12321. Review.</citation>
    <PMID>24628412</PMID>
  </reference>
  <reference>
    <citation>Zimny D, Szatkowska M, Połubok J, Maciaszek J, Machaj M, Barg E. [The use of metabolomics in medicine - some examples of oncological and metabolic diseases]. Pediatr Endocrinol Diabetes Metab. 2015;20(2):55-62. doi: 10.18544/PEDM-20.02.0003. Review. Polish.</citation>
    <PMID>26615014</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Dr Jane Kim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

